Department of Radiology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China.
J Med Virol. 2020 Oct;92(10):1922-1931. doi: 10.1002/jmv.25893. Epub 2020 Jun 2.
The aim of our study was to evaluate the therapeutic effect of antiviral drugs on coronavirus disease 2019 (COVID-19) pneumonia. Patients confirmed with COVID-19 pneumonia were enrolled and divided into seven groups according to the treatment option. Information including age, sex, and duration from illness onset to admission, clinical manifestations, and laboratory data at admission, and length of hospital stay were evaluated. The chest computed tomography (CT) imaging obtained at admission and after a 5-day treatment cycle were assessed. The clinical symptoms and laboratory tests at discharge were also assessed. At admission, no significant differences were found among the groups, including the duration from illness onset to admission, clinical symptoms, and main laboratory results. No significant differences were found among the groups in terms of the proportion of patients with pneumonia resolution (P = .151) after treatment or the length of hospital stay (P = .116). At discharge, 7 of 184 (4%) patients had a mild cough while their other symptoms had disappeared, and the proportion of patients with abnormal liver function and with increased leukocytes, neutrophils or erythrocyte sedimentation rate among the 184 patients were close to those at admission. According to the results, the inclusion of antiviral drugs in therapeutic regimens based on symptomatic treatment had no significant additional impact on the improvement in COVID-19 patients. In addition, the results of chest CT imaging, clinical manifestations, and laboratory tests at discharge were not completely consistent.
我们的研究目的是评估抗病毒药物对 2019 年冠状病毒病（COVID-19）肺炎的治疗效果。将确诊为 COVID-19 肺炎的患者纳入研究，并根据治疗方案分为七组。评估了包括年龄、性别、发病至入院时间、入院时临床表现和实验室数据以及住院时间在内的信息。评估了入院时和 5 天治疗周期后的胸部计算机断层扫描（CT）影像。还评估了出院时的临床症状和实验室检查。入院时，各组之间在发病至入院时间、临床症状和主要实验室结果方面无显著差异。治疗后肺炎吸收的患者比例（P = .151）或住院时间（P = .116）方面，各组之间无显著差异。出院时，184 例患者中有 7 例（4%）有轻度咳嗽，但其他症状已消失，184 例患者中肝功能异常、白细胞、中性粒细胞或红细胞沉降率升高的患者比例与入院时相近。根据结果，在对症治疗的基础上加入抗病毒药物治疗方案对 COVID-19 患者的改善没有显著的额外影响。此外，出院时的胸部 CT 影像、临床表现和实验室检查结果并不完全一致。
